Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinglong Jin

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Natural Products|January 12, 2010
Bis-spirolabdane-type diterpenoids from Leonurus sibiricusHyun Teak Moon, Qinglong Jin, Ji Eun Shin, et al.
Frontiers in Immunology|April 3, 2023
TR score: A noninvasive model to predict histological stages in patients with primary biliary cholangitisZhixin Tu, Yao Wang, Yan Wang, et al.
Experimental and Therapeutic Medicine|April 29, 2017
Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis BXu Li, Qinglong Jin, Hong Zhang, et al.
Virology Journal|January 7, 2021
Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatmentXiaomei Wang, Xiumei Chi, Ruihong Wu, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2024
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver functionJing Zhou, Hong Zhang, Hong Chen, et al.
Frontiers in Pharmacology|July 15, 2026
First-in-human study on the pharmacokinetics, safety, and tolerability of single escalating doses and multiple doses of XT1061, a novel core protein allosteric modulator, in healthy Chinese subjectsQingmei Li, Yue Hu, Dandan Wu, et al.
Archives of Pharmacal Research|December 6, 2012
A new triterpenoid from Alisma orientale and their antibacterial effectHong-Guang Jin, Qinglong Jin, A Ryun Kim, et al.
Expert Opinion on Investigational Drugs|December 11, 2020
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsHong Zhang, Cuiyun Li, Jingrui Liu, et al.
BMJ Open|August 21, 2019
Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational studyMingyuan Zhang, Ruihong Wu, Hongqin Xu, et al.
Mediators of Inflammation|January 11, 2013
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patientsJuan Lv, Qinglong Jin, Haibo Sun, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Natural Products|January 12, 2010
Bis-spirolabdane-type diterpenoids from Leonurus sibiricusHyun Teak Moon, Qinglong Jin, Ji Eun Shin, et al.
Frontiers in Immunology|April 3, 2023
TR score: A noninvasive model to predict histological stages in patients with primary biliary cholangitisZhixin Tu, Yao Wang, Yan Wang, et al.
Experimental and Therapeutic Medicine|April 29, 2017
Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis BXu Li, Qinglong Jin, Hong Zhang, et al.
Virology Journal|January 7, 2021
Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatmentXiaomei Wang, Xiumei Chi, Ruihong Wu, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2024
Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver functionJing Zhou, Hong Zhang, Hong Chen, et al.
Frontiers in Pharmacology|July 15, 2026
First-in-human study on the pharmacokinetics, safety, and tolerability of single escalating doses and multiple doses of XT1061, a novel core protein allosteric modulator, in healthy Chinese subjectsQingmei Li, Yue Hu, Dandan Wu, et al.
Archives of Pharmacal Research|December 6, 2012
A new triterpenoid from Alisma orientale and their antibacterial effectHong-Guang Jin, Qinglong Jin, A Ryun Kim, et al.
Expert Opinion on Investigational Drugs|December 11, 2020
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsHong Zhang, Cuiyun Li, Jingrui Liu, et al.
BMJ Open|August 21, 2019
Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational studyMingyuan Zhang, Ruihong Wu, Hongqin Xu, et al.
Mediators of Inflammation|January 11, 2013
Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patientsJuan Lv, Qinglong Jin, Haibo Sun, et al.
Pageof 5